BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191202
DTEND;VALUE=DATE:20191205
DTSTAMP:20260515T041924
CREATED:20190815T095332Z
LAST-MODIFIED:20190815T095403Z
UID:21972-1575244800-1575503999@www.pharmajournalist.com
SUMMARY:2nd Annual RNA Targeted Drug Discovery
DESCRIPTION:At a time when the previously untapped drug discovery opportunity promised within RNA opens up\, the 2nd RNA- Targeted Drug Discovery Summit returns to reunite the leading minds from large pharma\, innovative biotech and KOLs of academia to discuss unique discovery and development challenges that must be overcome for novel RNA targeted small molecule therapeutics to achieve their seemingly limitless potential. \n \nFor the 2nd year\, network with the KOLs and RNA pioneers\, to gain a comprehensive understanding on how to translate the first generation of RNA targeted small molecules into the clinic\, stimulate the discussion of successfully targeting RNA via interfering with RNA-protein interactions and seize the therapeutic opportunity in hand by re-defining the undruggable nature of RNA. \nDownload the Full Event Guide. \nWith 22 world-class speakers sharing their latest findings\, join those who are re-defining the undruggable nature of RNA: \n\nKevin Weeks\, Founder of Ribometrix; Professor of Chemistrym\, University of North Carolina\nFrank Slack\, Co-Founder of Twentyeight-Seven Therapeutics; Professor\, BIDMC\nKathryn McCabe\, Sr. Director of Business Development\, Eli Lilly\nMartin Pettersson\, Research Fellow\, Pfizer\nChristopher Barbieri\, Senior Investigator\, Bristol-Myers Squibb\nJennifer Petter\, Founder & CSO\, Arrakis Therapeutics\nYochi Slonim\, Co-founder & CEO\, Anima Biotech\nGerhard Mueller\, CSO\, Gotham Therapeutics\nChristopher R. Trotta\, VP\, Biology\, PTC Therapeutics\n\nThis is only some of the senior experts confirmed to present – check out the full speaker faculty and case studies here. \nOnce again join your RNA community at this translational and industry dedicated event focused on optimizing target validation\, improving drug-like properties & accelerating the translation of selective and bioactive RNA targeted small molecule therapeutics into human clinical trials. \nCheck out the official event guide for full speaker details or if you’re ready to register\, secure your place here.
URL:https://www.pharmajournalist.com/event/2nd-annual-rna-targeted-drug-discovery/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR